A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® (047/SI)
A Prospective Multicenter, Comparative, Randomized, Double-blind, Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® in Patients With Moderate to Severe Dry Eye Syndrome
Sponsor: SIFI SpA
This NA trial investigates Dry Eye Syndromes and is currently completed. SIFI SpA leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2022 — Jan 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Apr 2021 — Jun 2022 [monthly]
Recruiting NA
-
Jan 2021 — Apr 2021 [monthly]
Recruiting NA
-
Jun 2020 — Jan 2021 [monthly]
Recruiting NA
-
Dec 2019 — Jun 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Dec 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- SIFI SpA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Brest, France , Dijon, France , Lyon, France , Madrid, Spain , Marseille, France , Nice, France , Saint-Etienne, France , Seville, Spain , Tours, France and 1 more location